Novavax
Headquarters country
United States
Registry sponsor category
Industry
- Other names
- Novavax
- Company name
- Novavax
- Organisation type
- Industry
- Registered legal name
- Novavax, Inc.
- US industry code (SIC)
- Biological products, (no disgnostic substances)
- Registry sponsor category
- Industry
- Website
- https://www.novavax.com/
- SEC filer number (CIK)
- 0001000694
- Legal Entity Identifier (LEI)
- 529900J4GJHPEPQ23205
- Wikidata ID
- Q17072200
Related records
Trials (53)
- A Phase I Randomized, Observer-Blinded, Dose-Ranging Study in Healthy Subjects 24 to <72 Months of Age
- A Strain Change Study for SARS-CoV-2 rS Vaccines
- A Study Looking at the Effectiveness and Safety of a COVID-19 Vaccine in South African Adults
- A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom
- A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization
- A Study to Evaluate Safety and Immunogenicity of a COVID-19 Vaccine in People Living With HIV at Risk for SARS-CoV-2 (COVID-19)
- A Study to Evaluate the Efficacy of an RSV F Vaccine in Older Adults
- A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2
- A Study to Evaluate the Immune Response and Safety of a Seasonal Virus-Like Particle Influenza Vaccine in Healthy Young Adults
- A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
- A Study to Evaluate the Safety and Immunogenicity of COVID-19 and Influenza Combination Vaccine
- A Study to Evaluate the Safety and Immunogenicity of COVID-19 Vaccine and Influenza Combination Vaccine
- A(H7N9) VLP Antigen Dose Ranging Study With Adjuvant 1
- A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ Adjuvant
- A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 1
- A/H5N1 Virus-Like Particle Antigen Dose Ranging Study With Adjuvant 2
- Additional Recombinant COVID-19 Humoral and Cell-Mediated Immunogenicity in Immunosuppressed Populations
- Efficacy and Safety of NVX-CoV2705
- Evaluate the Safety and Immunogenicity of a Seasonal Influenza Virus-Like Particle (VLP) Vaccine in Older Adults
- Evaluate the Safety and Immunogenicity of a Seasonal Influenza VLP Vaccine (Recombinant) in Healthy Adults